Literature DB >> 21806327

PET and PET/CT in radiation treatment planning for prostate cancer.

Michael Pinkawa1, Michael J Eble, Felix M Mottaghy.   

Abstract

Molecular imaging by means of PET provides a method to study the metabolic activity of tumors in vivo. (18)F- or (11)C-choline and occasionally (18)F- or (11)C-acetate, are used as tracers for prostate cancer, reflecting the phospholipid metabolism. The hybrid technology PET/computed tomography significantly reduces image fusion mismatch. The role of molecular imaging is increasing in radiation treatment planning for prostate cancer. Local prostate cancer recurrence after primary radiation treatment usually originates at the location of the primary tumor. Focusing the dose escalation on the actual tumor is an option to increase tumor control without increasing toxicity. Image-guided radiotherapy and intensity-modulated radiotherapy are prerequisite technologies for applying the simultaneous boost concept. Clinical results are needed in the near future to support the effectiveness of the concept.

Entities:  

Mesh：

Year:  2011        PMID： 21806327     DOI： 10.1586/era.11.51

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  11 in total

1.  MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Authors:  Mingqian Tan; Susan M Burden-Gulley; Wen Li; Xueming Wu; Daniel Lindner; Susann M Brady-Kalnay; Vikas Gulani; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

Review 2.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

3.  Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity.

Authors:  Michael Pinkawa; Carolina Ribbing; Victoria Djukic; Jens Klotz; Richard Holy; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2015-05-26       Impact factor: 3.621

Review 4.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

5.  Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET/CT examinations.

Authors:  Benedikt J Schwaiger; David L Kopperdahl; Lorenzo Nardo; Luca Facchetti; Alexandra S Gersing; Jan Neumann; Kwang J Lee; Tony M Keaveny; Thomas M Link
Journal:  Bone       Date:  2017-04-24       Impact factor: 4.398

6.  Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.

Authors:  Marsha Schlenter; Vanessa Berneking; Barabara Krenkel; Felix M Mottaghy; Thomas-Alexander Vögeli; Michael J Eble; Michael Pinkawa
Journal:  Strahlenther Onkol       Date:  2018-03-06       Impact factor: 3.621

7.  The impact of [68Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer.

Authors:  Thorsten Frenzel; Milena Tienken; Merve Abel; Christoph Berliner; Susanne Klutmann; Dirk Beyersdorff; Rudolf Schwarz; Andreas Krüll; Peter Bannas
Journal:  Strahlenther Onkol       Date:  2018-03-23       Impact factor: 3.621

8.  Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.

Authors:  Tonghe Wang; Robert H Press; Matt Giles; Ashesh B Jani; Peter Rossi; Yang Lei; Walter J Curran; Pretesh Patel; Tian Liu; Xiaofeng Yang
Journal:  Br J Radiol       Date:  2019-04-09       Impact factor: 3.039

9.  Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost.

Authors:  Michael Pinkawa; Marc D Piroth; Richard Holy; Jens Klotz; Victoria Djukic; Nuria Escobar Corral; Mariana Caffaro; Oliver H Winz; Thomas Krohn; Felix M Mottaghy; Michael J Eble
Journal:  Radiat Oncol       Date:  2012-01-30       Impact factor: 3.481

10.  A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.

Authors:  Tonghe Wang; Jun Zhou; Sibo Tian; Yinan Wang; Pretesh Patel; Ashesh B Jani; Katja M Langen; Walter J Curran; Tian Liu; Xiaofeng Yang
Journal:  Br J Radiol       Date:  2020-01-06       Impact factor: 3.039
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.